A clinical trial for patients with high-grade\u00a0neuroendocrine tumors\u00a0is now open for enrollment at\u00a0Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.<\/p>\n
High-grade neuroendocrine cancer is a complex and aggressive condition that has seen few medical advances, in part because its rarity has subdued research investment. Patients have few options beyond conventional chemotherapy.<\/p>\n
The\u00a0new trial, headed by Aman Chauhan, M.D.,\u00a0leader of the\u00a0Neuroendocrine Tumor Program\u00a0at Sylvester, offers a fresh approach. Patients will receive a combination of immunotherapy<\/a> drugs and a tumor-busting “oncolytic” virus injected directly into the tumors.<\/p>\n Tumors in any organ, at any age<\/p>\n Neuroendocrine tumors originate from cells found throughout the body and can affect most organ systems. They most often attack the lungs, gastrointestinal tract, gynecological tract and prostate.<\/p>\n About one-sixth of neuroendocrine tumors are classified by pathologists as high grade. Survival rates from high-grade cancer vary with the site of disease, but most patients succumb within a year or two, said Dr. Chauhan. People older than 60 account for the majority of cases, but these aggressive tumors can strike people of any age.<\/p>\n Victims of high-grade disease include\u00a0Sean Stone, an emerging Hollywood producer who passed away last March at only 26 years of age, and Nichole Borchard, a vibrant mother of two young children who died in September 2024 at age 39. Her family established the\u00a0Nichole Borchard Foundation\u00a0to honor the legacy of “an extraordinary woman who fought like hell to live and get better.” And Stone’s family founded the\u00a0Sean Stone’s Neuroendocrine Carcinoma Fundraiser, which supports research at Sylvester.<\/p>\n Checkpoint inhibitors and “hot” tumors<\/p>\n In the new trial, Chauhan will combine immunotherapy drugs called checkpoint inhibitors with SVV-001 (Seneca Valley Virus-001), an oncolytic virus that has been tested for safety in previous trials.<\/p>\n Checkpoint inhibitors have broadened treatment options for a growing list of tumor types, from\u00a0melanoma<\/a>\u00a0to\u00a0lung cancer.<\/p>\n Very few high-grade neuroendocrine carcinomas respond to the drugs. But when they do, the effect is often long lasting.<\/p>\n The challenge is to increase the number of patients who fully respond to immunotherapy.<\/p>\n That’s where Seneca Valley Virus comes in. SVV doesn’t infect normal cells. It grows inside tumor cells and busts them open. When the tumor cells burst, they release their contents, activating the immune system. The virus then goes on to infect other tumors and keeps the chain reaction going.<\/p>\n The checkpoint inhibitors in turn amp up the immune response against tumor components. In the trial, patients will receive the checkpoint inhibitors nivolumab and ipilimumab.<\/p>\n Chauhan and colleagues\u00a0previously tested\u00a0the approach in preclinical cancer models. Tumors shrank and yielded durable responses, he said.<\/p>\n In those studies, the oncolytic virus turned immune “cold” tumors into “hot” tumors that respond to checkpoint inhibitors. The drugs in turn acted like “fuel to the fire,” strengthening the attack against the tumor, said Chauhan.<\/p>\n Biomarker boost<\/p>\n The new phase 1 trial will enroll about 36 people whose tumors have become resistant to or failed previous lines of therapy.<\/p>\n The aim is to find safe combination doses and to begin comparing effectiveness with historical data from standard-of-care treatment.<\/p>\n